

Harvard Medical School Curriculum Vitae

Date 2/20/2024

Prepared:

Name: Paul F. Dellaripa

Office Address: Brigham and Women's Hospital
Division of Rheumatology, Immunology, and Allergy
75 Francis Street, BTM 3
Boston, MA 02115

Home Address: 28 Meadow Lane
Needham, MA 02192

Work Phone: 617-732-5548

Work Email: pdellaripa@bwh.harvard.edu

Work FAX: 617-732-5505

Place of Birth: Hartford, CT

Education

1985	BA	Biology	College of the Holy Cross Worcester, MA
1989	MD	Medicine	University of Connecticut School of Medicine Farmington, CT

Postdoctoral Training

7/89-6/90	Intern	Medicine	New England Deaconess Hospital, Boston, MA
7/89-6/92	Clinical Fellow	Medicine	Harvard Medical School Boston, MA
7/90-6/92	Resident	Medicine	New England Deaconess Hospital
7/92-6/94	Clinical Fellow	Rheumatology	Tufts New England Medical Center, Boston, MA
7/95-6/96	Clinical Fellow	Critical Care Medicine	Lahey Clinic, Burlington, MA and New England Deaconess Hospital
7/95-9/96	Clinical Fellow	Medicine	Harvard Medical School

Faculty Academic Appointments

7/96-8/06	Clinical Instructor	Medicine	Harvard Medical School
7/97-8/06	Assistant Professor	Medicine	Tufts University School of Medicine, Boston, MA
9/06	Associate Professor	Medicine	Tufts University School of

9/06-9/13	Assistant Professor	Medicine	Medicine Harvard Medical School
10/13-	Associate Professor	Medicine	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

7/94-6/95	Affiliate Staff	ICU and Rheumatology	Deaconess Waltham Hospital, Waltham, MA
7/95-6/97	Fellowship Staff	Medicine	Deaconess Waltham Hospital
7/96-8/06	Staff Physician	Rheumatology	Lahey Clinic
9/06-	Physician	Medicine/Division of Rheumatology, Inflammation, and Immunity	Brigham and Women's Hospital (BWH), Boston, MA

Major Administrative Leadership Positions

Local

2000	Associate Course Director, Topics of Internal Medicine Course	Lahey Clinic
2001	Associate Director, Update in ACLS	Lahey Clinic
2001	Associate Director, CME Topics in Internal Medicine Course	Lahey Clinic
2000-2006	Associate Program Director, Internal Medical Residency Program	Lahey Clinic
2000-2002	Medical Director, Advanced Cardiac Life Support Program	Lahey Clinic
2002-2006	Chairman, Department of Rheumatology	Lahey Clinic
2007-2010	Co-director, Interstitial Lung Disease Clinic	BWH
2008-2016	Assistant Director STRATUS Center for Medical Simulation	BWH
2008-2017	Medical Director, Ambulatory Infusion Center	BWH
2012-2022	Co-course director and participant, DVD, CME course "Board Review in Rheumatology"	BWH and Harvard Medical School

Committee Service

Local

1994-1995	Critical Care Committee	Deaconess Waltham Hospital Member
1995-2006	Code Committee	Lahey Clinic
	1995-2006	Member
	2000-2006	Chairperson
1996-2006	Critical Care Committee	Lahey Clinic Member
1996-2006	Curriculum and Clinical Competence Committee	Lahey Clinic Member

1997-2000	Section of Medical Ethics	Lahey Clinic
2006-	Steering Committee	Member Division of Rheumatology, Immunology, and Allergy, BWH
2009-2011	Medical Records Committee	Member BWH Member, Rheumatology Division Representative
2018- 2018-	Financial Aid Advisory Committee Partners Health Sustainability Group/Climate Action Council BWH	Harvard Medical School MGB/BWH
2019-	Needham Green Solar Team	Town of Needham MA
2019-	Consensus Expert Panel (CEP) Members for Management and Treatment Guidelines for Pulmonary Manifestations in Sjogren's	Sjogren's Foundation
2022	Climate Action Planning Committee	Town of Needham
2002	Climate Change and Health Curriculum	Harvard Medical School
2002	Climate and Sustainability Faculty Working Group BWH	BWH

Professional Societies

1996-	American College of Rheumatology (ACR)	
1996-		Member
2005-2006		Member, Professional Meetings Committee
2005-2006		Abstract Reviewer Vasculitis Section
2007-		ILD Study Group leader and founder
2007-2010		Member Executive Board, Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Connective Tissue Disease/Interstitial Lung Disease
2010-2013		Abstract reviewer on Clinical Aspects of RA Co-Chair, Abstract Selection Committee, Annual Conference
1998-	American College of Physicians	
1998-		Fellow
1999-2006	International Network for the Study of the Systemic Vasculitides (INSSYS)	
1999-2006		Member

Editorial Activities

Ad hoc Reviewer

Arthritis and Rheumatism

Arthritis Care and Research

British Medical Journal Open

Chest
J Clinical Rheumatology
Journal of the American Medical Association
Respiratory Medicine
Seminars in Arthritis and Rheumatism

Other Editorial Roles

1995	ABIM test question writer	American Board of Internal Medicine
1997-	Editorial Board Member	Journal of Intensive Care Medicine
2006-2023	Up-to-Date Writer and Section Editor	Up-to-Date

Honors and Prizes

1985	Graduated <i>cum laude</i>	College of the Holy Cross	
1985	Presidential Service Award	College of the Holy Cross	Service to the College
1989	Commencement Speaker	University of Connecticut School of Medicine	
1990	James L. Tullis Award Recipient PGY1	New England Deaconess Hospital	Clinical excellence
1996- 2001	Outstanding Teacher in Medicine Clerkship	Tufts University School of Medicine	Teaching
2001	Excellence in Teaching Award	Lahey Clinic	Teaching
2008	Excellence in Tutoring	Harvard Medical School Human Systems Rheumatology	Teaching
2011	Excellence in Teaching Award	Jean Jackson Excellence in Teaching Award, BWH house staff	Teaching
2011	Executive Leadership Training Program	BWH and Harvard Business School	Recognized for leadership development
2019	Subspecialty Clinical Teacher Award	BWH	Teaching
2022	Distinguished Clinician Award	BWH	Clinical care

Report of Funded and Unfunded Projects

Funding Information

Past

- 1999 Pegylated Tumor Necrosis Factor (TNF)-Receptor Trial
Amgen (Investigator initiated)
Co-Investigator, Physician joint examiner (PI Jonathan Kay)
Major Goal: Efficacy of TNF receptor antagonist in Rheumatoid Arthritis (RA)
- 1999 Osteoarthritis Study
Merck (Investigator initiated)
Co-Investigator (PI Jonathan Kay)
A randomized, placebo and active compared controlled parallel group double-blind two-part study assessing safety and efficacy of MK-0663 versus Naproxen in patients with osteoarthritis the knee or hip.
- 1999 RA Study LCID 99-065
Amgen (Investigator initiated)
Co-Investigator (PI Jonathan Kay)
Multicenter blinded randomized placebo controlled trial to study the effect of IL-1ra in rheumatoid arthritis
- 2000-2002 Giant Cell Arteritis
INSSYS (Investigator initiated)
Co-Investigator (PI David Hellman)
Quality of Life Assessment in Giant Cell Arteritis
- 2000-2003 Investigation of the effects of Residronate in patients with medial compartment knee osteoarthritis
Proctor and Gamble (Investigator initiated)
Co-Investigator (PI, Stephen Goldring MD)
A randomized double blind parallel multicenter placebo controlled study on the effect of Residronate
- 2002-2003 Evaluation of the safety and efficacy of Anakinra and etanercept
Amgen 2001-016 (Investigator initiated)
PI
Multicenter double blinded study to evaluate the safety and efficacy of Anakinra and etanercept in subjects with rheumatoid arthritis using Methotrexate.
- 2002-2003 Evaluation of the efficacy and safety of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor type I
Amgen Study LCID 2001-028 (Investigator initiated)
PI
Randomized placebo controlled multicenter study to evaluate efficacy and safety of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor type I given twice weekly to subjects with rheumatoid arthritis receiving Methotrexate.
- 2002-2005 Proteomic evaluation of BAL fluid in patients with interstitial lung disease (ILD) in the rheumatic diseases
Tufts University School of Medicine Division of Pulmonary Medicine
PI (unfunded)
Major Goal: Assessment of proteomic signatures in RA pts with ILD
- 2002-2006 Rheumatoid Arthritis Treatment Evaluation Registry (RATER)
Vanderbilt University School of Medicine

- PI Jonathan Kay)
Major Goal: Establishment of an early RA cohort
- 2004-2005 Measurement of serum KL-6 levels in patients with interstitial lung diseases and rheumatic diseases
Lahey Clinic
PI: P Dellaripa, internal funding
- 2004-2006 Major Goal: Analysis of KL-6 serum levels as markers in ILD.
Development of a survey instrument for measuring quality of life in patients with giant cell arteritis (Phase II)
INNSYS (Investigator initiated)
Co-Investigator (PI David Hellman)
- 2007 A multicenter trial to develop a survey instrument for giant cell arteritis (Phase II)
ILD: Natural history and outcomes
Self funded
PI (Paul Dellaripa internal funding)
Goal: Determine diagnostic and therapeutic outcomes in a population of patients evaluated in a multidisciplinary ILD clinic
- 2007 Support for Excellence in Educational Development (SEED) grant to initiate a simulation curriculum within the Department of Medicine (DOM) Medical Residency program
PI (\$10,000)
Goal: Develop a simulation curriculum as part of the orientation curriculum for incoming internal medicine interns.
- 2009-2011 Open label trial of Rituxan in ILD associated with RA
Genentech
PI (\$40,000)
Goal: Determine the safety and efficacy of B cell deletion in the treatment of ILD associated with RA
- 2010-2011 ARTEMIS Idiopathic Pulmonary Fibrosis (IPF): A phase III trial double blinded randomized trial utilizing Ambrisentan in IPF
Gilead Sciences (Investigator initiated)
Co-Investigator (PI Ivan Rosas)
Goal: Investigate the role of endothelin antagonists in the treatment of IPF
- 2011-2012 A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with IPF
Boehringer Ingelheim Pharmaceuticals (Investigator initiated)
Co-Investigator (PI Ivan Rosas)
Goal: Determine the efficacy of a novel tyrosine kinase inhibitor in the treatment of IPF
- 2011-2013 RA and ILD Proteomic markers and clinical correlates. In conjunction with the University of Miami
American College of Rheumatology
Site PI (no funds, study PI Dana Aschermann)
Goal: Identify novel proteomic biomarkers that will identify and be unique to patients with RA and ILD.
- 2011-2016 MYORISK: identifying triggers to disease in the antisynthetase syndrome in

- conjunction with NIH
 NIH
 Site PI (National PI, Frederick Miller)
 Goal: Attempt to identify infectious and environmental triggers which lead to the development of the anti-synthetase syndrome.
- 2014-2019 Towards evidence-based monitoring of low dose methotrexate (LDM): CIRT Ancillary Study.
 NIH RO1 HL119718-01A1
 Role: Adverse event reviewer (PI, Daniel Solomon)
 Goal: The discovery and clinical use of markers associated with a greater likelihood of AE from LDM would provide an important public health benefit to rheumatic disease patients if the CIRT trial shows reduction on cardiovascular events with LDM.
- 2016-2017 Screening for interstitial lung disease in rheumatoid arthritis.
 BWH
 Role: Co-investigator (PI Tracey Doyle)
 Goal: Utilizing the BRASS registry, we attempt to establish the association between well-accepted clinical parameters and the presence of interstitial lung disease in subjects with rheumatoid arthritis.
- 2017-2020 Scleroderma Lung Study III (SLSIII)
 Genentech (investigator initiated)
 Role: Co-investigator (Site PI, Michael Roth)
 Goal: This multicenter clinical study will test the efficacy of oral pirfenidone and mycophenolate mofetil (MMF) vs. placebo and MMF in patients affected with scleroderma-interstitial lung disease in a randomized, double-blind, placebo-controlled 18-month trial.
- 2017-2021 Phase 2 safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis interstitial lung disease.
 Genentech
 Role: Co-Investigator (Site PI, Ivan O. Rosas)
 Goal: Randomized prospective placebo control trial, investigator-initiated, will test the safety, tolerability and efficacy of oral pirfenidone in patients affected with rheumatoid arthritis-associated interstitial lung disease
- 2017-2021 Abatacept for the treatment of myositis-associated interstitial lung disease (AttackMyILD)
 Bristol Myers Squibb (Investigator initiated)
 Role: Co-investigator (Site PI, Rohit Aggarwal)
 Goal: This multicenter clinical study will evaluate the efficacy and safety of abatacept in myositis ILD (antisynthetase syndrome) in a randomized, double-blind, placebo-controlled 6-month trial followed by a 24-week open-label extension.

Current

- 2019- CLASS project (Classification Criteria of Anti-synthetase Syndrome)
 ACR/EULAR collaborative
 Role: site PI (PI:Rohit Aggarwal) (\$0)

Goal: multicenter, international study with the goal of providing phenotypic and natural history data on patients with anti-synthetase syndrome.

2023- Sjogrens Delphi exercise, myositis and peripheral nervous system guidelines project.

Unfunded Current Projects

2022- Co-investigator: Cancer Screening consensus guidelines in Myositis (IMACS consortium)

Report of Local Teaching and Training

Teaching of Students in Courses

Tufts University School of Medicine

1992-1993	Introduction to Clinical Medicine 2 medical students per session	Eight 3 hr sessions/year for 2 years
1992-1993	Vasculitis Workshop 20 2 nd year medical students	3 hrs of instruction
1996	Ambulatory Medicine Clerkship at Lahey Clinic 3yr medical students per semester	18 hrs of instruction
1997	Vasculitis and Rheumatology Workshop 15 2 nd year medical students	4 hrs of instruction
2003	The Musculoskeletal Examination 10 2 nd year medical students	One 2 hr session
2003, 2004	Rheumatology and Vasculitis Workshop 20 2 nd year medical students	6 hrs of instruction
2004	Presentation The musculoskeletal Examination 20 2 nd year medical students	2 hrs of instruction
2004	Chief's Rounds 4 medical students	3 hrs of instruction
2004	Outpatient Ambulatory Instruction 4 3 rd year medical students	2 hrs per week for 9 months
2005	Musculoskeletal Pathophysiology Course 20 2 nd year medical students	4 hrs of instruction
2021	Climate Change in Health 30 medical students	1 hr

Harvard Medical School

2000	Rheumatology and Musculoskeletal Curriculum 15 2 nd year medical students	12 hrs of instruction
------	--	-----------------------

2001- 2003, 2005	Musculoskeletal Examination 15 2 nd year medical students	One 2 hr session
2002- 2003	Introduction to Clinical Medicine 10 2 nd year medical students	One 2 hr session
2007	Musculoskeletal Endocrine and Reproductive Pathophysiology Course 6 2 nd year medical students	11 hrs of instruction
2007	Musculoskeletal Pathophysiology Course 10 2 nd year medical students	6 hrs of instruction
2007, 2008	Musculoskeletal Pathophysiology Course - Scleroderma Clinical Correlation 100 2 nd year medical students	1 hr of instruction
2008	Outpatient Rheumatology Clinic 1 medical school student	One 4 hr session
2008	The Musculoskeletal Examination 15 Harvard –MIT medical school students	1 hr session
2009	Objective structured clinical exam (OSCE) Course –Otolaryngology Assessment 8 medical school students	1 hr session
2009	Musculoskeletal Examination 20 2 nd year medical students	1 hr session
2009- 2011	Human Systems – Scleroderma 100 2 nd year medical students	1 hr session
2010	Outpatient Rheumatology clinic medical student	6 hr session
2012	Human Systems -Scleroderma and other Fibrosing disorders 100 2 nd year medical students	1 hr session
2012	The Muskoskeletal Joint exam 100 2 nd year medical students	1 hr session
2017	Pizza and Pizzaz Lunch HST Conf RA: Clinical and pathogenesis 30 students	1 hr session
2018	HMS Year 1 Disclosure 1 student	1 hr session
2020	HMS TPC case conference 12 students	3 hr session
2022	HMS Tutorial Climate and Health 12 students	1 hr session
2022	HMS in-patient ITU service	10 hrs total

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

1996	Residents Report 20 internal medicine residents	Lahey Clinic 40 hrs/year
1996	Resident Critical Care Conference – Airway Management in the Critically Ill 20 internal medicine residents	Lahey Clinic 1 hr/year
1996	Resident Critical Care Conference – Line Placement in the Intensive Care Unit 20 internal Medicine residents	Lahey Clinic 1 hr/year
1996	Resident Noon Conference –1. The Musculoskeletal system; 2. Techniques of soft tissue injection; 3. Update in Rheumatologic Testing 20 internal Medicine residents	Lahey Clinic 3 1 hr lectures/year
1996	Pulmonary and Critical Care Conference - Immunologic mediators in critical illness 20 internal Medicine residents	Lahey Clinic 1 hr/year
1996	Rheumatology – Resident Board Review Series 10 internal Medicine residents	Lahey Clinic 1 hr/year
1997	Resident Noon Conference –1. ACLS Review; 2. Airway Management; 3. Musculoskeletal Examination 20 internal medicine residents	Lahey Clinic 3 1 hr lectures/year
1997	Resident Critical Care Conference – Sedation in the Intensive Care Unit 20 internal medicine residents	Lahey Clinic 1 hr/year
1998	Resident Noon Conference –1. ACLS Review; 2. Airway Management 20 internal medicine residents	Lahey Clinic 2 1 hr lectures/year
1998, 1999	Pulmonary Critical Care Conference – Treatment of Pulmonary Manifestations of Rheumatic Diseases 10-20 internal medicine residents	Lahey Clinic 1 hr/year
1998	Rheumatology Monthly Conference – B2 Glycoprotein I Antibody 20 internal medicine residents	Lahey Clinic 1 hr/year
1999	How to run a code – Medical Housestaff Conference 10 internal medicine residents	Lahey Clinic 1 hr/year
1999	Pulmonary and Critical Care Conference Corticosteroid induced osteoporosis 10 internal medicine residents	Lahey Clinic 1 hr/year
2000	Critical Care Housestaff Lecture Series – Pulmonary	Lahey Clinic

	Hemorrhage, Diagnosis and Treatment	
	20 internal medicine interns & residents	1 hr/year
2000	Pulmonary and Critical Care Conference – Genetic Polymorphisms in Critical Illness	Lahey Clinic
	10 internal medicine residents	1 hr/year
2000	Housestaff Ethics and Critical Care Conference – Withdrawal of therapy in critical illness	Lahey Clinic
	20 internal medicine interns and residents	1 hr/year
2001, 2002, 2005	Critical Care Housestaff Lecture Series – Sedation in the ICU	Lahey Clinic
	20 internal medicine interns & residents	1 hr/year
2001	Pulmonary and Critical Care Conference – Pulmonary and Critical Care Issues in Rheumatic Diseases	Lahey Clinic
	12 internal medicine residents	1 hr/year
2002	General Medicine Conference – Introduction to Musculoskeletal Medicine	Lahey Clinic
	6 internal medicine residents	1 hr/year
2002	Housestaff conference – Airway management and code scenarios	Lahey Clinic
	20 internal medicine interns & residents	1 hr/year
2004	Critical Care Conference – Sedation in the critically ill patient	Lahey Clinic
	20 internal medicine interns & residents	1 hr/year
2004	Medical Simulation Conference– Critical events and code scenarios	Lahey Clinic
	20 internal medicine residents	1 hr/year
2006	Visiting physician – Ward Rounds	Faulkner Hosp. Boston, MA
	4 residents, 2 medical students	10 hrs
2007	Morning Report, Attending discussant	BWH
	20 students/residents	5 hrs/year
2007	Preceptor – Arthritis and Rheumatic Diseases Center	BWH
	1 medical resident	6 hrs/year
2008	GMS Subspecialty Medical Residency Conference – Clinical Case Presentation	BWH
	40 residents	1 hr/year
2008	Lead discussant, Clinical Path Internal Medicine conference	BWH
	40 residents/students	5 hrs/year

2008	Morning Report Discussant 15 internal medicine residents	Faulkner Hospital 3 hrs/year
2008	Chief's Walk Rounds 20 residents /students	BWH 1 hr/year
2009	GMS Subspecialty Medical Residency Conference- Simulation Workshop –Joint examination and injection techniques 8 medical residents	BWH 2 hr/year
2009	Morning Report 2 internal medicine residents	BWH 3 hrs/year
2009	Preceptor, Medical Resident, Rheumatology Presentation 6 internal medicine residents	BWH 1 hr/year
2009	Medical Residency Noon Conference Update in Vasculitis 40 internal medicine residents	Faulkner Hospital 1 hr/year
2010	Joint examination and aspiration techniques 20 internal medicine residents	BWH 1 hr/year
2011	Attending discussant Morning Report 20 residents/students	BWH 1 hr
2011	Co-discussant CPC, 'Fever of Unknown Origin' 40 internal medicine residents	BWH 1 hr
2011	Attending discussant Morning Report 40 internal medicine residents	BWH 3 hrs
2011	Attending discussant, Clinical Reasoning Conference 40-50 internal medicine residents	BWH 1 hr
2011, 2012	Master Clinician Teaching Series – presenter and discussant 60 internal medicine residents	BWH 1 hr
2012	Attending discussant Morning Report 20 internal medicine residents	Faulkner Hospital 1 hr
2012	Attending discussant Morning Report 20 internal medicine residents	BWH 1 hr
2012	Clinical Pathology Conference 20 internal medicine residents	VA Hospital, West Roxbury 1 hr
2012	Clinical Pathology Conference 20 residents	BWH 1 hr
2013	Morning Report 20 medical residents and students	Faulkner Hospital 1 hr

2013	Noon conference Update on Vasculitis 40 medical residents	BWH 1 hr
2014	Noon Neurology Conference 40 residents	BWH 1 hr
2015	Morning Report 10 residents	BWFH 2 hrs
2016	Morning Report 40 residents	BWH 4 hrs
2017	Morning Report 10 residents	BWFH 2 hrs
2017	Morning Report 40 residents	BWH 2 hrs
2017	Orientation Interns Stratus Simulation 70 interns	BWH 1 hr
2017	Disclosure discussion; intern orientation 120 interns	BWH 1 hr
2017	Noon Conference: Intro to Rheumatology 10 interns	BWFH 1 hr
2018	Morning Report 50 residents	BWH and BWFH 3 hrs
2018	Disclosure intern orientation 120 interns	BWH 1 hr
2018	Clinic teaching rheum 3 residents/3 med students	BWH 18 hrs
2019	Noon conference 15 residents/medical students	BWFH 3 hrs
2019	Morning Report 20 residents	BWH 3 hrs
2019	Disclosure Intern Orientation 100 residents	BWH 1 hr
2020	Morning Report 15 residents/HMS students	BWFH 1 hr
2020	CRC Conference 30 residents	BWH 1 hr
2020	Clinical Noon Conference 10 residents, several med students	BWFH 4 hrs
2020	Intern Orientation 100 residents	BWH 1 hr
2020	Noon Conference	BWH

	30 residents	1 hr
2021	Noon Resident Rounds, Climate Change in Health 30 residents	BWH 2hrs
2021	Resident Report 25 residents	BWH 3 hrs
2021	Residents Report 10 residents	BWFH 3 hrs
2022	BWH Master Clinician Conference 40 residents	BWH 1hr
2022	Noon Resident Round – Climate Change in Health 40 residents	MGH-BWH 1 hr
2022	IM Senior Conference Rheumatology Pearls 10 residents	BWH 1 hr
2022	Morning Report 25 residents	BWH 2 hrs
2022	Medical Resident Teaching out-patient Rheumatology Clinic 9 residents	BWH 9 hrs
2022	Teaching of residents on rounds ITU 6 residents	BWH 20 hrs
2023	Morning report 10 medical residents	BWFH and BWH 4 hr

Clinical Supervisory and Training Responsibilities

1991-1992, 1995	Doctor-Patient instructor 6 HMS second year students	New England Deaconess Hospital	3 hrs per semester
1994-1995	Inpatient ICU Preceptor	Deaconess Waltham Hospital	1-2 hrs/month for one year
1996-2006	Ambulatory Rheumatology Clinic Preceptor	Lahey Clinic	One session/week
2006-	Ambulatory Rheumatology Clinic Preceptor	BWH	12 sessions/year
2007, 2008	Ward Attending, General Medical Service	BWH	1 month/year
2008	Ambulatory Rheumatology Clinic, Preceptor for Harvard Medical- 15 MIT students	BWH	One 3 hr session
2009	Ward attending Integrated Teaching Unit 6 residents/2 students	Faulkner Hospital	2 weeks/year
2010- 2023	Ward attending Integrated Teaching Unit/GMS service	BWH	2-5 weeks/year 24 hrs per week

Formal Teaching of Peers (e.g., CME and other continuing education courses)

No presentations below were sponsored by outside entities

1997, 1998	The Musculoskeletal Examination and Techniques of Joint Injection and Aspiration Lahey Clinic Course	One lecture/year Waterville Valley, NH
1999	New Treatments in Rheumatoid Arthritis Lahey Clinic Internal Medicine Review Course	Lecture Portsmouth, NH
2003	Update in Rheumatoid Arthritis Topics of Internal Medicine Course. Lahey Clinic	Lecture Kennebunkport, ME
2007-20	Scleroderma, Sjogrens, Myositis Harvard Medical School Intensive Review of Internal Medicine	One 1 hr lecture/year Boston, MA
2008-10	Joint Aspiration and Injection Harvard Medical School Course Office Practice in Primary Care	Lecture, 4 hrs/year Boston, MA
2009	Joint Aspiration/Injections BWH Hospitalist Service	1 hr lecture Boston, MA
2010	Joint Aspiration/Injections Internal Medicine Residents Department of Medicine, BWH	1 hr lecture Boston, MA
2011	Primary care preceptor rheumatology teaching session, The Joint Exam Department of Medicine, BWH	1 hr lecture Boston, MA
2011,2014-2015, 2020	Harvard Medical School CME Review Course Rheumatology, Lung Diseases in the Rheumatic Diseases	1 hr lecture Boston, MA
2011-2013	Clinical Pearls in Rheumatology Harvard Medical School Primary Care Review Course	1 hr lecture/year Boston, MA
2013	Instructor, Research in Medical Education Workshop, BWH Instructor, Management Leadership Track Program, BWH	6 hours Boston, MA 1 hr Boston MA
2018	Grand Rounds Update on RA	Faulkner Hospital 1hr delete here move below
2020	Climate and Health: Div of Nephrology, GI and Hospital Medicine, Rheumatology. Allergy and Immunology, BWH	Boston, MA 5 hrs Is this CME – if soo need more info
2021	Climate and Health	Vanderbilt Univ

	IM Housestaff 25 residents	1 hr ?CME OR MOVE TO NATIONAL INVITED BELOW
2022	BWH Pulmonary Review Course: The Lung and Rheumatic Disease 100 MDs NUMBER NOT NEEDED	Boston, MA 1 hr
2022-2023	Internal Medicine Review Course where	12 hrs

Local Invited Presentations

No presentations below were sponsored by outside entities

1998	PCP prophylaxis in Vasculitic Syndromes. Department of Medicine, Lahey Clinic
1999	Definitions of Death, ICU ethics case conference Medical Ethics Committee, Lahey Clinic,
1999	Protean Manifestations of Giant Cell Arteritis (Grand Rounds) Department of Medicine, Lahey Clinic
2000	Lofgren's Syndrome (Grand Rounds) Department of Medicine, Lahey Clinic
2000	Drug Induced Vasculitic Syndromes, Rheumatology monthly conference Lahey Clinic
2002	Interstitial Lung Disease in the Rheumatic disease Beth Israel Deaconess Medical Center, Boston, MA
2003	Interstitial Lung Disease in the Rheumatic Diseases (Rheumatology Grand Rounds) Massachusetts General Hospital, Boston, MA
2005	Interstitial Lung Disease in the Rheumatic Diseases (Rheumatology Grand Rounds), BWH
2010	Interstitial Lung Disease (Medical Grand Rounds) Faulkner Hospital
2010	Interstitial Lung Disease (Medical Grand Rounds) North Shore Hospital
2018	Update on RA (Medical Grand Rounds) Faulkner Hospital

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Regional, National, and International Invited Presentations and Courses

Regional

No presentations below were sponsored by outside entities

- 1999 Giant Cell Arteritis/ Grand Rounds
Lawrence Memorial Hospital, Lawrence, MA
- 2000 Grand Rounds/Update: Giant Cell Arteritis/
Hale Hospital, Lawrence, MA
- 2000 Pulmonary and Critical Care Issues in Rheumatic Diseases/ Invited presentation
Rheumatology weekly conference, Division of Rheumatology, Tufts/New England
Medical Center, Boston, MA
- 2002 Interstitial lung disease and the Rheumatic diseases/ Invited presentation
Pulmonary and Critical Care Conference. Tufts/New England Medical Center
- 2002 Pulmonary Manifestations of Rheumatic Diseases/ Invited presentation
St. Elizabeth Hospital, Dept of Pulmonary and Critical Care Medicine, Boston, MA
- 2005 Pulmonary Diseases in the Rheumatic Disorders/ Grand Rounds
UMASS-Memorial Medical Center, Worcester, MA
- 2005 Interstitial Lung Disease in the Rheumatic disease/ Rheumatology Grand Rounds
Tufts New England Medical Center
- 2008 Interstitial Lung Disease in the Rheumatic Diseases/ Rheumatology Grand Rounds
Tufts New England Medical Center
- 2009 The Role of the Medical Evaluation in Asylum and Immigration Cases/ Invited
Presentation
Brown University, Providence, RI
- 2011 Interstitial Lung Disease/ Pulmonary Grand Rounds
Lahey Clinic
- 2012 Rheumatic Diseases in Inflammatory Bowel Disease (IBD) and Arthritis/ Invited
presentation
IBD Conference, Boston University School of Medicine, Boston, MA
- 2014 Interstitial Lung Disease in the Rheumatic disease/ Pulmonary Grand Rounds
Tufts New England Medical Center
- 2016 Interstitial Lung Disease in the Rheumatic disease/ Rheumatology Grand Rounds
BU Medical Center
- 2018 Lung Disease in the Rheumatic Diseases/ Rheumatology Grand Rounds
UMASS-Memorial Medical Center
- 2020 Interstitial Lung Disease in the Rheumatic disease/ Pulmonary and Rheumatology
Grand Rounds
Tufts New England Medical Center
- 2021 RA ILD/ Rheumatology Grand Rounds
UMASS-Memorial Medical Center

National

- 1999 Pulmonary and Critical Care Issues in the Rheumatic Diseases/ Lecturer
American College of Rheumatology Annual Meeting, Boston, MA
- 2002 Pulmonary Manifestations of Rheumatic Diseases/ Lecturer
American College of Rheumatology Spring Meeting, Chicago, IL
- 2004 Interstitial Lung Diseases in Rheumatic Disorders/ Lecturer
Meet the Professor Session, American College of Rheumatology Annual Meeting,
San Antonio, TX

- 2005 Interstitial Lung Diseases in the Rheumatic Diseases/ Lecturer
Meet the Professor Session, American College of Rheumatology Annual Meeting, San Diego, CA
- 2006 Interstitial Lung Diseases in the Rheumatic Diseases/ Lecturer
Meet the Professor Session, American College of Rheumatology Annual Meeting, Washington, DC
- 2007 Integration of simulation in the curriculum of an Internal Medicine Residency/
Lecturer
Association of Program Directors, Minneapolis, MN
- 2009 Interstitial Lung Diseases in the Rheumatic Diseases/ Lecturer
Meet the Professor Session, American College of Rheumatology Annual Meeting, Philadelphia, PA
- 2010 Interstitial Lung Diseases in the Rheumatic Diseases/ Lecturer
Meet the Professor Session, American College of Rheumatology Annual Meeting, Atlanta, GA
- 2011 The role of vessel size in the diagnosis of vasculitis/ Lecturer
National Meeting, Society for Vascular Medicine, Boston MA, June 2011.
- 2011 ILD and the rheumatic diseases (Meet the Professor); Moderator, Rheumatoid Arthritis (RA) Clinical Aspects Abstracts II; and Moderator, ILD Study Group
American College of Rheumatology Annual Meeting, Chicago, IL
- 2012 Lung Disease in the Rheumatic Diseases/ Rheumatology Grand Rounds
Hospital for Special Surgery, New York, NY
- 2012-13 Moderator, RA Clinical Aspects Abstracts II and Moderator, ILD Study Group
Session American College of Rheumatology Annual Meetings, Washington DC and San Diego CA
- 2016 ILD and the Rheumatic Diseases Meet the Professor/ Lecturer
American College of Rheumatology Annual Meeting, Washington, DC
- 2016 Challenges in Clinical Trials Design Speaker, Clinical Research Conference
American College of Rheumatology, Washington, DC
- 2016 ILD and the Rheumatic Diseases/ Lecturer
Annual New York Thoracic Society Meeting
- 2017 ACR/EULAR consensus conference ILD and rheumatic diseases/ Speaker and subgroup leader, Washington DC
- 2017 ILD and the Rheumatic Diseases Meet the Professor/ Lecturer
American College of Rheumatology San Diego CA
- 2017 Hot topics in Myositis/ Speaker
American College of Rheumatology Annual Meeting, San Diego CA
Mayo Clinic Pulmonary Manifestations of Connective Tissue Disease. Oct 2021
- 2017 SLE and Sjogrens in the Lung. Orlando Florida
- 2018 Lung Diseases in the rheumatic diseases. Meet the Professor/ Lectuer.
American College of Rheumatology Annual Meeting, Chicago IL
- 2018 Moderator ILD Study Group
American College of Rheum Annual Meeting, Chicago IL
- 2018 Fellows Roundtable discussion facilitator and speaker
American College of Rheumatology Chicago 30 fellows
- 2019 ILD/ Grand Rounds
Division Rheumatology, Washington University, St. Louis MO

- 2019 Lung Disease in the Rheumatic Diseases/ Rheumatology Grand Rounds
Hospital for Special Surgery, New York, NY
- 2019 Study Group Moderator and Speaker, ILD and Rheumatic Diseases.
and Meet the Professors Speaker ACR, Atlanta, GA
- 2021 Mayo Clinic Pulmonary Manifestations of Connective Tissue Disease. Oct 2019
SLE and Sjogrens in the Lung. Orlando Florida
- 2021 Bechara Rheumatology Research Update: RA and lung disease/ Lecturer.
Rheumatology Society of Puerto Rico. Lung Disease in the Rheumatic Diseases,
San Juan, PR
- 2021 Mayo Clinic Pulmonary Manifestations of Connective Tissue Disease. Oct 2021
SLE and Sjogrens in the Lung. Orlando Florida
- 2021 ACR Convergence 2021 speaker: Clinical Science: Digital ischemia in the critically
ill.
- 2021 ACR Convergence /Moderator: Climate Pollution and the Rheumatic Diseases
Medical Grand Rounds, The lung and RA. New York Presbyterian Hospital Queens
- 2022 Climate change and Health U. Chicago Medical Grand Rounds, Chicago, IL
- 2023 Moderator, Myositis Abstract Session ACR
San Diego, CA
- 2023 SLE and Sjogrens in the Lung/ Lecturer
Mayo Clinic Jacksonville. FL

International:

- 2017 Lung diseases in the rheumatic diseases: Paradigm Shift / Lecturer
International Symposium of Targeted Therapeutics, Mandeleau, France
- 2020 Interstitial Pneumonia with autoimmune features/ Lecturer.
2nd Annual International Symposium on Autoimmune Lung Disease, Barcelona
Spain
- 2021 Department of State Update in Primary Care Course 2021. *Due to the COVID19
Pandemic and associated travel bans, this course was held virtually
- 2021 The Lung and Myositis/ Grand Rounds
Division of Rheumatology Sun Yat Sun Hospital China.
- 2022 RA ILD, diagnosis, screening and treatment/ Lecturer.
Review Course Canadian Rheumatology Association Annual Meeting, Ottawa
Canada
- 2022 RA ILD: management the rheumatologist perspective and roundtable discussion.
International symposium on ILD in the rheumatic diseases. Ottawa Canada

Report of Clinical Activities and Innovations

Current Licensure and Certification

- 1990 Diplomate of National Board of Medical Examiners
- 1991 Massachusetts Medical License
- 1992 Board Certification Internal Medicine, American Board of Internal Medicine
- 1994 Subspecialty Certification in Rheumatology, American Board of Internal Medicine
- 1997 Board Certification Critical Care Medicine, American Board of Internal Medicine

2002 Recertification, Internal Medicine and Rheumatology
 2012 Recertification, Internal Medicine
 2022 Recertification BLS and ACLS

Practice Activities

1994-1995	Inpatient ICU, Ambulatory Care in Rheumatology	Deaconess Waltham Hospital	40 hrs per week
1996-2006	Ambulatory Care and Critical Care Medicine	Rheumatology, Lahey Clinic	Eight sessions per week
2006-	Ambulatory Care/ attending Ward attending	Rheumatology, BWH Internal Medicine, BWH	Eight sessions per week, clinic 1 month per year, hospital

Clinical Innovations

Developed the ILD Clinic at BWH, a multidisciplinary clinic that is composed of rheumatologists, pulmonologists, radiologists and pathologists that has developed a regional and national reputation for the treatment and study of patients with inflammatory and fibrosing lung disorders. I conceived of and initiated the operation of this clinic in 2007.

Developed the Simulation curriculum for the Internal Medicine Residency at BWH in 2008. This curriculum utilizes medical simulation as part of the educational curriculum in the medical residency program and integrates challenging clinical cases from real cases at the BWH that are developed into simulated scenarios and then integrated into the education curriculum for the medical residents on their integrated teaching unit (ITU) rotation.

Helped Develop the Teleconference Program with the Indian Health Service (IHS) in Shiprock, New Mexico and the Division of Rheumatology at BWH in 2011. In this program, physicians from Brigham and Women’s Hospital interact with physicians from the INH discussing difficult cases and interviewing patients via teleconference and advising on clinical care of challenging clinical cases.

Developed the inaugural three-part series “Climate and Health” on the curriculum in conjunction with the medical-residency program BWH and I am a member of the Climate Action Council at BWH working to engage at a grassroots level to educate our colleagues and develop nascent sustainability projects within each division of the Department of Medicine. Also, developed the inaugural clinical curriculum thru the ACR annual meeting 2021 on “Climate change, pollution and rheumatology” In addition, I have developed the first educational efforts within the American College of Rheumatology, leading and organizing two clinical sessions and study groups to build a sustained effort to integrate climate science into the rheumatology curriculum at the ACR.

Report of Education of Patients and Service to the Community

No presentations below were sponsored by outside entities

Education of Patients and Service to the Community

1993-1997, 2003-2005 Physician Volunteer: Walk for Hunger, Boston, MA
1996-2000 Advanced Cardiac Life Support Instructor, Lahey Clinic
1995-1996 American Board of Internal Medicine question writer: Rheumatology
1996-1997 Volunteer case reviewer, Massachusetts Board of Registration
1997- Physician examiner, Physicians for Human Rights
2004-2010 Human Rights Committee Member, Town of Needham, MA,
Chairperson 2008-2012
2010- Volunteer Physician and Telemedicine conference participant,
Indian Health Service, Shiprock, NM
2011- Board member, Advisory Council, Indian Health Service
2021 Physician Expert, New England Sjogren's Society Meeting **WHERE**

Recognition

2009, 2010, 2013-2019	Top Doctors	Castle & Connelly
2009-2012	Peoples' Choice	Peoples' Choice Inc.
2010	America's Top Doctors	US News & World Report
2017-2022	Boston Top Doctors	Boston Magazine

Report of Scholarship

Peer reviewed publications in print or other media

Research investigations

1. Boston A, Roubenoff R, **Dellaripa P**, Nadeau M, Sutherland P, Wilson P, Jacques P, Selhub J. Validation of an abbreviated oral methionine loading test. *J Clin Chem*. 1995;41:948-49.
2. Roubenoff R, **Dellaripa P**, Nadeau MR, Abad LW, Muldoon BA, Selhub J, Rosenberg IH. Abnormal homocysteine metabolism in rheumatoid arthritis. *Arthritis Rheum*. 1997;40(4):718-22.
3. Hellman DB, Uhlfelder ML, Stone JH, Jenkes MW, Cid MC, Guillevin L, Moreland L, **Dellaripa PF**, Hoffman GS, Merkel PA, Spiera R, Brown L, Hernandez Rodriguez J, Rubin H. Domains of health related quality of life important to patients with giant cell arteritis. *Arthritis Rheum*. (*Arthritis Care and Research*) 2003;49(6):819-25.
4. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Csasciola-rosen L, Hong G, **Dellaripa PF**, Highland KB. Clinical Profile of Anti-Pl12 autoantibody: Cohort study and review of the literature. *Chest* 2009;135(6):1550-6.
5. Mahr AD, Edberg JC, Stone JH, Hoffman GS, St. Clair EW, Specks U, **Dellaripa PF**, Seo P, Spiera RF, Rouhani FN, Brantly ML, Merkel PA. Alpha 1-antitrypsin deficiency-related alleles Z and S and the risk for Wegener's granulomatosis *Arthritis Rheum*. 2010;62(12):3760-7.
6. Castellino F, Goldberg H, **Dellaripa PF**. The impact of rheumatologic evaluation in the management of patients with interstitial lung disease. *Rheumatology* 2011;50:483-93
7. Skog A, Peyre S, Pozner CN, Thorndike M, Hicks G, **Dellaripa PF**. Assessing physician leadership styles: Application of the situational leadership model to transitions in patient

- acuity. *Teach Learn Med.* 2012;24(3):225-30.
8. Kelley JM, Monach PA, Ji C, Zhou Y, Wu J, Tanaka S, Mahr AD, Johnson S, McLear C, Cuthbertson D, Carette S, Davis JC, **Dellaripa PF**, Hoffman GS, Khalidi N, Langford CA, Seo P, St. Clair EW, Specks U, Stone JH, Spiera RF, Ytterberg SR, Merkel PA, Edberg JC, Kimberly RP. IgA and IgG ANCA Engagement of Fc receptors influences granulomatosis with polyangiitis (Wegener's) in a genetically dependent fashion. *Proc Natl Acad Sciences* 2011;108(51):20736-41.
 9. Chung S, Xie G, Roshandel D, Sherva R, Edberg J, Kravitz M, **Dellaripa PF**, Hoffman GS, Seo P, Speck U, Spiera R, St Clair E, Stone J, Plenge R, Merkel P, Monach P. Meta-analysis in granulomatosis with polyangiitis reveals shared susceptibility with rheumatoid arthritis. *Arthritis Rheum.* 2012;64(10):3463-71.
 10. Matteson EL, Bongartz T, Ryu J, Crowson CS, Hartman TE, **Dellaripa PF**. Open label pilot trial of the safety and clinical effects of Rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. *Open Journal of Rheumatology and Autoimmune diseases.* 2012;2:53-8.
 11. Harlow L, Rosas IO, Gochucio B, Mikulis T, **Dellaripa PF**, Oddis C, Ashermann D. Identification of citrullinated heat shock protein 90 isoforms autoantigens in rheumatoid arthritis-associated interstitial lung disease. *Arthritis Rheum.* 2013;65(4):869-79.
 12. Xie G, Roshandel D, Sherva R, Monach PA, Lu Y, Kung T, Carrington K, Zhang SS, Pulit SL, Ripke S, Carette S, **Dellaripa PF**, Edberg JC, Hoffman GS, Khalidi N, Langford CA, Mahr AD, St Clair EW, Seo P, Specks U, Spiera RF, Stone JH, Ytterberg SR, Raychaudhuri S, de Bakker PIW, Farrer LA, Amos CI, Merkel PA, Siminovitch KA. Granulomatosis with polyangiitis (Wegener's) is associated with HLA-DPB1*04 and SEMA6A gene variables. Evidence from genome wide analysis. *Arthritis Rheum* 2013 ;65(9) ;2157-68.
 13. Doyle T, Lee J, **Dellaripa PF**, Lederer J, Matteson E, Ascherman D, Glassberg M, Ryu J, Danoff S, Brown K, Collard H, Rosas I. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2014 145(3):454-63.
 14. Doyle T, **Dellaripa PF**, Batra K et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. *Chest.* 2014;146 (1):41-50.
 15. Saketkoo LA, Mittoo S, Huscher D, Khanna D, **Dellaripa PF**, Distler O et al. Connective tissue related interstitial lung disease and idiopathic pulmonary fibrosis: provisional core-sets of domain and instruments for use in clinical trials. *Thorax* 2014;69;428-36.
 16. Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, Ge SX, Huang H, Lin Q, Liu W, Cai Y, Koontz D, Fuhrman CR, Golzarri MF, Liu Y, Hatabu H, Nishino M, Araki T, **Dellaripa PF**, Oddis CV, Rosas IO, Ascherman DP. Biomarkers of rheumatoid arthritis associated interstitial lung disease. *Arthritis Rheum.* 2015;Jan.67(1):28-38
 17. Rao D, Wei K, Merola JF, O'Brien WR, Takvorian SU, **Dellaripa PF**, Schur PS. The significance of anti-myeloperoxidase and anti-proteinase 3 antibodies in the absence of anti-neutrophil cytoplasmic antibody immunofluorescence positivity *J Rheum online* 2015 doi:10.3899.
 18. White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, Moore BB, Cheng L, Doyle TJ, Villalba J, **Dellaripa PF**, Rosas IO, Kurtis JD, Martinez FJ. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. [Am J Respir Crit Care Med.](#) 2016 Nov 15;194(10):1242-51.
 19. Courtwright A, El-Chemaly S, Dellaripa PF, Goldberg H. Survival and outcomes after lung

- transplantation for non-scleroderma connective tissue-related interstitial lung disease. [J Heart Lung Transplant](#). 2017 Jul;36(7):763-9. doi: 10.1016/j.healun.2016.12.013. Epub 2016 Dec 31.
20. Sparks JA, Iversen MD, Yu Z, Triedman NA, Prado MG, Miller Kroouze R, Kalia SS, Atkinson ML, Mody EA, Helfgott SM, Todd DJ, **Dellaripa PF**, Bermas BL, Costenbader KH, Deane KD, Lu B, Green RC, Karlson EW. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements: A randomized controlled trial. *Arthritis Care Res. (Hoboken)*. 2017 Oct 12. doi: 10.1002/acr.23411. [Epub ahead of print].
 21. Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J, Pinder BD, Zhao A, Zhang J, Qian D, Ripke S, Pagnoux C, Carette S, Chung S, Cuthbertson D, Davis JC, Jr., **Dellaripa PF**, Forbess L, Gewurz-Singer O, Hoffman GS, Khalidi N, Koenig C, Langford CA, Mahr AD, McAlear C, Moreland L, Seo EP, Specks U, Spiera RF, Sreih A, St. Clair W, Stone JH, Ytterberg SR, Elder JT, Ochi T, Hirano N, Edberg JC, Falk RJ, Amos CI, Siminovitch KA for the Vasculitis Clinical Research Consortium. Identification of functional and expression polymorphisms associated with risk for anti-neutrophil cytoplasmic autoantibody-associated vasculitis, [Arthritis Rheum](#). 2017; May;69(5):1054-66. doi: 10.1002/art.40034. Epub 2017 Apr 6.
 22. Doyle TC, Dhillon N, Mdan R, Cabral F, Fletcher EA, Kootz DC, Aggarwal R, Osorio JC, Rosas IO, Oddis CV **Dellaripa PF**. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multi-center retrospective case review. *J Rheum*. 2018;45(6):841-50.
 23. Schiffenbauer A, Fahhihi-Kashani D, O'Hanlon TP, Flegel WA, Adams SD, Targoff IN, Oddis CV, Ytterberg SR, Aggarwal R, Christopher-Stine L, Shamim EA, **Dellaripa P**, Danoff SK, Mammen AL, Miller FW. The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. *Sem Arthritis Rheum*. 2018;48(3):504-12.
 24. Sreih AG, Ezzedine R, Leng L, Fan J, Yao J, Reid D, Piecychna M, Carette S, Cuthbertson D, **Dellaripa P**, Hoffman GS, Khalidi NA, Koenig CL, Langford CA, Mahr A, McAlear CA, Maksimowicz-Mckinnon K, Monach PA, Seo P, Specks U, St Clair EW, Stone JH, Ytterberg SR, Merkel PA, Bucala R. Role of macrophage migration inhibitory factor in granulomatosis with polyangiitis. *Arthritis Rheum*. 2018;70(12):2077-86.
 25. Sparks JA, Iversen MD, Yu Z, Triedman NA, Prado MG, Miller Kroouze R, Kalia SS, Atkinson ML, Mody EA, Helfgott SM, Todd DJ, **Dellaripa PF**, Bermas BL, Costenbader KH, Deane KD, Lu B, Green RC, Karlson EW. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements: A randomized controlled trial. *Arthritis Care Res*. 2018; Jun;70(6):823-33. PMID: 29024454; PMCID: PMC5897224.
 26. Sparks JA, Doyle TJ, He X, Pan B, Iannaccone CK, Frits ML, **Dellaripa PF**, Rosas IO, Lu B, Weinblatt ME, Shadick NA*, Karlson EW*. Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis. *ACR Open Rheum*. 2018 DOI: 10.1002/acr2.1001 *Contributed equally.
 27. Huang S, He X, Doyle TJ, Zaccardelli A, Marshall AA, Friedlander HM, Blaustein RB, Smith EA, Cui J, Iannaccone CK, Mahmoud TG, Weinblatt ME, **Dellaripa PF**, Shadick NA, Sparks JA. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. *Clin Rheum*. 2019;38(12):3401-2.
 28. Solomon J, Matson S, Kelmenson L; Chung J, Hobbs S, Rosas I, **Dellaripa P**, Doyle T, Poli S, Esposito A, Visser A, Marin A, Amigues I, Fernández Pérez E, Brown K, Mahler M, Heinz D, Cool C, Deane K, Swigris J, Demoruelle HK. IgA antibodies directed against

- citrullinated protein antigens are elevated in patients with idiopathic pulmonary fibrosis. *Chest* 2019;157(6):1513-21
29. Oliveira R, Waxman A, Hoover P, **Dellaripa P**, Systrom D. Pulmonary vascular and right ventricular burden during exercise in interstitial lung disease. *Chest* 2020;158(1):350-8.
 30. Solomon DH, Glynn RJ, Karlson EW, Corrigan C, Colls J, Macfadyen J, Barbhuiya M, Berliner N, **Dellaripa PF**, Everett BM, Pradhan AD, Hammond SP, Murray M, Rao D, Ritter S, Rutherford A, Sparks JA, Stratton J, Suh DH, Tedeschi SK, Vanni KM, Paynter NP, Idker PM. Adverse effects of low-dose methotrexate: A randomized trial. *Ann Intern Med.* 2020; 176(6):369-380. doi: <https://doi.org/10.7326/M19-3369>.
 31. Huang S, Doyle TJ, Hammer MM, Byrne SC, Huang W, Marshall AA, Iannaccone CK, Huang J, Feathers V, Weinblatt ME, **Dellaripa PF**, Shadick NA, Sparks JA. Rheumatoid arthritis related interstitial lung disease detected on computerized tomography chest imaging *Semin Arthritis Rheum.* 2020; 50(6): 1216-25.
 32. Lee. A Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's Chest 2021 159(2):683-698 Consensus Panel Expert (I was in the consensus panel)
 33. Kronzer VL, Huang W, **Dellaripa PF**, Huang S, Feathers V, Lu B, Iannaccone CK, Gill RR, Hatabu H, Nishino M, Crowson CS, Davis JM 3rd, Weinblatt ME, Shadick NA, Doyle TJ, Sparks JA. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. *J Rheumatol.* 2021 May;48(5):656-63. doi: 10.3899/jrheum.200863. Epub 2020 Nov 15. PMID: 33191286; PMCID: PMC8096643.
 34. Solomon JJ, Swigris JJ, Kreuter M, Polke M, Aronson K, Hoffmann-Vold AM, **Dellaripa PF** The attitudes and practices of physicians caring for patients with rheumatoid arthritis-interstitial lung disease: An international survey. *Rheumatology* 2021;61(4):1459-67.
 35. Kuczmariski TM, Fox J, Katznelson E, Thakral D, Aung K-K, Moore E, Eisen J, Slutzman JE, LaRocque R, Solomon CG, Furie GL, **Dellaripa PF**. Climatizing the Internal Medicine Residency Curriculum: A Practical Guide for Integrating the Topic of Climate and Health into Resident Education, *J Climate Change Health*, 2021,100067,ISSN 2667-2782,<https://doi.org/10.1016/j.joclim.2021.100067>.
 36. Aung K, Chaitoff A, Fischer H, **Dellaripa PF**. Applying an environmental lens to value-based care: A resident-driven pilot project to limit laboratory testing on an internal medical ward service. *J Climate Change Health.* 2021, 100075,ISSN 2667-782. <https://doi.org/10.1016/j.joclim.2021.100075>.
 37. Matteson, EL, Kelly C, Distler JHW, Hoffman-Void AM, Seibold JR, Mitto S, **Dellaripa PF**, Aringer M, Pope J et al. for the INBUID Trial. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. *Arthritis Rheum* 2022; 34(6):1039-47.
 38. Esposito AJ, Sparks JA, Gill RR, Hatabu H, Schmidlin EJ, Hota PV, Poli S, Fletcher EA, Xiong W, Frits ML, Iannaccone CK, Prado M, Zaccardelli A, Marshall A, **Dellaripa PF**, Weinblatt ME, Shadick NA, Rosas IO, Doyle TJ. Screening for preclinical parenchymal lung disease in rheumatoid arthritis. *Rheumatology* 2022; 61(8):3234-45.
 39. Wu X, Jeong Y, Poli de Friás S, Easthausen I, Hoffman K, Oromendia C, Taheri S, Esposito AJ, Quesada Arias L, Ayaub EA, Maurer R, Gill RR, Hatabu H, Nishino M, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, **Dellaripa PF**, Cho AMK, Kim DY, Rosas IO, Martinez FJ, Doyle TJ. Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis. *Thorax* 2022;77:1041-4.
 40. Santacroce L, **Dellaripa PF**, Costenbader K, Collins J, Feldman C. Association of area-level heat and social vulnerability with recurrent hospitalizations among individuals with

- rheumatic conditions. *Arthritis Care Res* 2023 Jan;75(1):22-33.
41. McDermott G, Gill R, Gagne S, Byrne S, Huang W, Cui J, Prisco L, Zaccardelli A, Martin L, Kronzer VL, Moll M, Cho MH, Shadick N, **Dellaripa PF**, Doyle T, Sparks JA. Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset. *Rheumatology (Oxford)*. 2022 Nov 28;61(12):4915-4923. doi: 10.1093/rheumatology/keac152. PMID: 35289841; PMCID: PMC9707325.
 42. Joshua J, Solomon JJ, Danoff S, Woodhead F, Hurwitz S, Maurer R, Glaspole I, **Dellaripa PF**, Goptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest I, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perella MA, Lynch D, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg H, Rosas IO, for the TRAIL1 Network Investigators. A randomized, double-blinded, placebo-controlled, Phase 2 study of safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis interstitial lung disease. *Lancet Resp Med*. 2023 Jan;11(1):87-96.
 43. Tukpah A-MC, Rose JA, Seger DL, **Dellaripa PF**, Hunninghake GM, Bates DW. Development and validation of algorithms to build an electronic health record based cohort of patients with systemic sclerosis. 2023. *PLoS ONE* 18(4): e0283775.
 44. Roofeh D, Brown KK, Kazerooni EA, Tashkin D, Assassi S, Martinez F, Wells AU, Raghu G, Denton CP, Chung L, Hoffmann-Vold AM, Distler O, Johannson KA, Allanore Y, Matteson EL, Kawano-Dourado L, Pauling JD, Seibold JR, Volkmann ER, Walsh SLF, Oddis CV, White ES, Barratt SL, Bernstein EJ, Domsic RT, Dellaripa PF, Conway R, Rosas I, Bhatt N, Hsu V, Ingegnoli F, Kahaleh B, Garcha P, Gupta N, Khanna S, Korsten P, Lin C, Mathai SC, Strand V, Doyle TJ, Steen V, Zoz DF, Ovalles-Bonilla J, Rodriguez-Pinto I, Shenoy PD, Lewandoski A, Belloli E, Lescoat A, Nagaraja V, Ye W, Huang S, Maher T, Khanna D. Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. *Rheumatology (Oxford)*. 2023 May 2;62(5):1877-86. doi: 10.1093/rheumatology/keac557. PMID: 36173318; PMCID: PMC10152284.
 45. Swigris J, **Dellaripa PF**, Solomon JJ. Reliability and responsiveness of the D-12 and validity of its scores as a measure of dyspnea severity in patients with rheumatoid arthritis-related interstitial lung disease. *BMJ Open Respir Res*. 2023 Sep;10(1):e001872. doi: 10.1136/bmjresp-2023-001872. PMID: 37748807; PMCID: PMC10533789.
 46. Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, Machado PM, McHugh N, Selva-O'Callaghan A, Schmidt J, Tansley SL, Vleugels RA, Werth VP, International Myositis Assessment and Clinical Studies Group, Cancer Screening Expert Group, Aggarwal R. International Guidelines for Cancer Screening for IIM (I was a Member of the voting panel on recommendations). *Nat Rev Rheumatol*. 2023;19:8015-17. <https://doi.org/10.1038/s41584-023-01045-w>.
 47. Juge PA, Hayashi K, McDermott G, Vanni K, Kowalski E, Qian G, Bade K, Saavedra A, Dieudé P, **Dellaripa P**, Doyle TJ, Sparks JA. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. *Semin Arthritis Rheum*. 2024 (In Press).
 48. McDermott GC, Hayashi K, Yoshida K, Juge PA, Moll M, Cho MH, Doyle TJ, Kinney GL, **Dellaripa PF**, Wallace ZS, Regan EA, Hunninghake GM, Silverman EK, Ash SY, San Jose Estepar, R, Washko GR, Sparks JA. Associations and mortality impact of machine learning-derived quantitative computed tomography parenchymal lung features in rheumatoid arthritis and non-RA comparators in a multicenter prospective cohort of smokers. *Rheumatology (Oxford)*, 2024 (in press)
 49. Elahee M, Mueller A, Wang R, Marks K, Sasaki T, Cao Y, **Dellaripa P**, Fava A, Boin F, Rao D. A PD-1hi CD4+ T cell population with a cytotoxic phenotype is associated with interstitial lung

disease in systemic sclerosis. *Arthritis Rheum.* 2024 (in press)

Other peer-reviewed publications:

1. Up to Date (uptodate.com): Author of section on lung diseases in systemic lupus erythematosus (SLE) and dermatomyositis, 2009.
2. Up to Date (uptodate.com): Author of section on lung diseases in systemic lupus erythematosus (SLE) and rheumatoid arthritis, 2022.

Non-peer reviewed scientific or medical publications/materials in print or other media

Reviews, chapters, monographs and editorials:

1. **Dellaripa PF.** Diagnosis and treatment of gout in the intensive care unit. *J Intensive Care Med.* 1997;12(4):206-12.
2. **Dellaripa PF,** Beamis JF. Percutaneous tracheostomy. *Interventional pulmonary medicine.* Ed. New York:McGraw Hill Publishing; 1998;285-94.
3. Vernovsky I, **Dellaripa PF.** PCP prophylaxis in patients with rheumatic diseases on immunosuppressive therapy. *J Clin Rheum.* 2000;6(2):95-101.
4. **Dellaripa PF.** Toxic shock syndrome. *J Intensive Care Med.* 2000;15(6):314-20.
5. **Dellaripa PF.** Commentary on B. White et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. In: *Ann Int Med* 2000; 132:947-54; In: *J Clin Rheum.* 2001;7(1):51-2.(editorial).
6. **Dellaripa PF,** Giansiracusa DF, Liu NYN, Strongwater SL. Rheumatologic and collagen vascular disorders in the intensive care unit and vasculitis in the intensive care unit. In: Irwin RS and Rippe JM, Eds. *Intensive Care Medicine.* 5th edition. Philadelphia: Lippincott, Williams and Wilkins. Publication 2003;2083-112/2140-50.
7. **Dellaripa PF,** Howard D. Vasculitis in the intensive care unit. In: Irwin RS and Rippe JM, Eds. *Intensive Care Medicine.* 6th edition. Philadelphia: Lippincott, Williams and Wilkins, 2007 (book chapter).2276-86.
8. Badra K, **Dellaripa PF.** Addressing interstitial lung disease and the rheumatologic diseases. *J Musculoskeletal Med.,* December 2007.
9. **Dellaripa PF,** Howard D, Nutritional issues and vasculitis. In *Nutrition and Rheumatic Disease.* Coleman LA., ed. 1st edition. Totowa: Humana Press 2008.pg 215-26.
10. K Phillips, Flaherty KR, Matteson EC, Bongartz T, Bathon J, **Dellaripa PF.** Interstitial lung disease in rheumatoid arthritis. *Current Rheum Rev* 6(2). 2010, 120-6.
11. **Dellaripa PF,** Rosas IO. The lung in rheumatic disease. In Hochberg M, ed. *Textbook of Rheumatology.* 5th edition publication Oct 2010.
12. **Dellaripa PF,** Howard D. Vasculitis in the intensive care unit. In: Irwin RS, Rippe JM, eds. *Intensive Care Medicine.* 7th edition. Philadelphia: Lippincott, Williams and Wilkins, 2012, 2064-72.
13. **Dellaripa PF,** Todd D. Rheumatologic emergencies. In: McKean SM, Ross JJ, Ginsberg J, editors. *Principles and Practice of Hospital Medicine.* New York: McGraw-Hill, 2012, 2125-30.
14. Goldberg H, **Dellaripa PF.** Pulmonary manifestations of SLE. In Massarotti E, Schur PH, eds. *SLE: Clinical Manifestations.* Springer, 2012; 115-26.

15. **Dellaripa PF**. Systemic vasculitis. In Singh AK, Loscalzo J, editors. *Intensive Review of Internal Medicine*. Oxford, 2012; 271-76.
16. Castelino FV, **Dellaripa PF**. Scleroderma, pathogenesis and clinical manifestations. In Tsokas G, ed. *Encyclopedia of Medical Immunology*. Springer 2013
17. Rao DA, **Dellaripa PF**. Extrapulmonary manifestations of sarcoidosis. *Rheum Dis Clinics North America* 2013;39(2):277-97.
18. Rosas IO, **Dellaripa PF**, Lederer DJ, Khanna D, Young LR, Martinez FJ. NHLBI workshop on the primary prevention of chronic lung diseases: Interstitial lung disease. *Ann Am Thoracic Soc*. 2014;11(3):S169-77.
19. Chansakul T, **Dellaripa PF**, Doyle TJ, Madan R. Intra-thoracic rheumatoid arthritis: imaging spectrum of typical findings and treatment related complications. *Eur J Radiol*. 2015;84(10):1981-91.
20. Doyle TJ, **Dellaripa PF**. Lung manifestations of rheumatic diseases. *Chest*. 2017;152(6):1283-95.
21. **Dellaripa PF** Interstitial lung disease in the connective tissue diseases: A paradigm shift in diagnosis and treatment. *J Clin Immunol*. 2018;186:71-3.
22. Fischer A, Streck ME, Cotton V, **Dellaripa PF** et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. *Arthritis Rheum*. 2019;71(2):182-95.
23. Doyle TJ, **Dellaripa PF**. Management of lung disease in myositis. In *Managing Myositis*. Aggarwal R., ed. Springer 2019. Pg 315-322
24. Esposito A, Chou S, Madan R, Doyle TJ, **Dellaripa PF**. Rheumatoid arthritis and the lung. *Clinics Chest Medicine* 2019. 545-60.
25. Huang S, Kronzer VL, **Dellaripa PF**, Deane KD, Bolster MB, Nagaraja V, Khanna D, Doyle TJ, Sparks JA. Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. *Curr Treatm Opt Rheumatol*. 2020
26. Rodriquez JV, Doyle TJ, **Dellaripa PF**. Pulmonary manifestations of SLE. In *Lahita's Systemic Lupus Erythematosus*. Lahita R , Costenbader K, Bucala R, Manzi S, Khamashta M, eds. 2021.
27. Esposito A, **Dellaripa PF**. Interstitial lung disease with autoimmune features. In *The Lung and Autoimmune Diseases*. Atzari F, Gomez-Puerta J, Sellares J, eds . 2021.
28. Giblin GT, Murphy L, Stewart GC, Desai AS, Di Carli MF, Blankstein R, Givertz MM, Tedrow UB, Sauer WH, Hunninghake GM, **Dellaripa PF**, Divakaran S, Lakdawala NK. Cardiac sarcoid when and how to treat inflammation. *Cardiac Failure Review* 2021;7:e17. DOI: <https://doi.org/10.15420/cfr.2021.16>.
29. **Dellaripa PF**, Bush T, Miller F, Feldman C. Climate change and the role of the rheumatologist notes from the field. *Arthritis Rheum*. 2023; 75:(1)1-3.

Books/Text Books for the medical or scientific community

1. **Dellaripa PF**. Rheumatologic and Immunologic Problems in the Intensive Care Unit, section editor. In: Irwin RS, Rippe JM, editors. *Manual of Intensive Care Medicine*, 4^{th-6th} Edition. Philadelphia: Lippincott, Williams and Wilkins; 2006, 2010, 2014.
2. **Dellaripa PF**. Vasculitis in the Intensive Care Unit. In: Irwin S. Rippe JM, editors. *Manual of Intensive Care Medicine*, 4th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2006. 848-50.

3. **Dellaripa PF**. Vasculitis in the Intensive Care Unit. In: Irwin S. Rippe JM, editors. Manual of Intensive Care Medicine, 5th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2010. 970-73.
4. **Dellaripa PF**. Howard D. Vasculitis in the Intensive Care Unit. In: Irwin S. Rippe JM, editors. Manual of Intensive Care Medicine, 6th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2014. 1127-31.
5. **Dellaripa PF**, Fischer A. and Flaherty KR, editors, Pulmonary Manifestations of Rheumatic Diseases, Springer, 2014.
6. Doyle, Dellaripa PF, Rosas RA Biomarkers in Rheumatoid Arthritis ILD in Lung Disease in Rheumatoid Arthritis. Fischer A and Lee JS Springer, eds., 2017.
7. **Dellaripa PF**. Howard D. Vasculitis in the Intensive Care Unit. In: Irwin S. Rippe JM, editors. Manual of Intensive Care Medicine, 7th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2017. 2064-72.
8. **Dellaripa PF**, Todd D. Rheumatologic emergencies. In: McKean SM, Ross JJ, Dressler DD, Scheurer DB. editors. Principles and Practice of Hospital Medicine. New York: McGraw-Hill, 2017. 2017-23.
9. **Dellaripa PF**. Howard D. Vasculitis in the Intensive Care Unit. In: Irwin S., Rippe JM, editors. Manual of Intensive Care Medicine, 8th Edition. Philadelphia: Lippincott, Williams and Wilkins; In press 2024.

Professional educational materials or reports, in print or other media

Multimedia/Nonprint:

1. Developed an instructional CD/video utilizing simulation to teach physicians/nurses behavioral and technical techniques in emergency medical management. "How to run a code successfully," 2005.
2. Goodman, RP, Vaidya A, Dellaripa PF. Interactive Medical Case. An unusual case of abdominal pain. New England Journal of Medicine. 2013
3. Developed an instructional video utilizing simulation in the teaching of disclosure techniques in medical education online 2015
4. Podcast ACR on Air: How environmental factors can impact patient care, 2023.
5. Vumedi recording: Climate change and the relationship to Rheumatologic Disease. 2024

Clinical Guidelines and Reports:

1. **Dellaripa PF**, Eisenhauer A. Bilateral percutaneous balloon angioplasty of the axillary arteries in a patient with giant cell arteritis and upper extremity ischemic symptoms not responsive to corticosteroids. J Rheumatol. 1998;25:1429-33.
2. Sarwar A, **Dellaripa PF**, Beamis J. A 51-year -old man with fever, ulnar neuropathy, and bilateral pleural effusions. Chest 1999;116:1105-7.
3. **Dellaripa PF**, Weschler ME, Roth ME, Drazen J. Recurrent panniculitis in a 46-year-old male while receiving treatment with the leukotriene modifying agent's zileuton or montelukast. Mayo Clinic Proc. 2000;75:643-5.
4. Derosa F, Craven D, Shaz D, Campagna A, **Dellaripa PF**, Khettry U. Invasive Aspergillosis soon after TNF-alpha neutralizing antibody (Infliximab) therapy: a possible healthcare associated case? Infection Control and Hospital Epidemiology 2003;24(7):477-82.
5. Weinreb N, Rabinowitz A, **Dellaripa PF**. Treatment of Felty's Syndrome with Rituximab. J Clin Rheum. 2006;12(1):48.
6. Gorman SR, Duncan RF, **Dellaripa PF**. Necrotizing myositis complicated by diffuse alveolar

hemorrhage and sepsis following corticosteroid therapy. *Infections in Medicine*. 2006;23(10):480.

7. Stoll ML, Solomon DH, Batra KL, Simard JF, Karlson EW, **Dellaripa PF**, Weinblatt ME, Glass R, Shadick NA. TNF α Inhibitors May Improve Asthma Symptoms: A Case Series of 12 Patients with Rheumatoid Arthritis and Asthma. *J Clin Rheum*. 2009;15(4):198-200.
8. Velez NF, Ishizawar RC, **Dellaripa PF**, Saavedra AP, Laga AC, Murphy GF, Fisher DS, Kupper TS, Vleugels RA. Full Facial Edema: A Novel Presentation of Subcutaneous Panniculitis-like T-cell Lymphoma. *J Clin Oncology* 2012,
9. Henderson, LA, Loring SH, Gill RR, Liao KP, Ishizawar R, Kim S, Perlmutter-Goldberg R, Rothman D, Son MB, Stoll, ML, Zemel LS, Sandborg C, **Dellaripa PF**, Nigrovic PA. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. *J Rheumatol*. 2013;Mar;40(3):273-81.
10. Goodman, R, **Dellaripa PF**, Miller, AL, Loscalzo J An Unusual case of abdominal pain, *N Engl J Med*. 2014;370:70-5.
11. Divakaran S, **Dellaripa PF**, Kobzik L, Levy B, Loscalzo J. All that wheezes. *N Engl J Med* 2017;377:477-84 DOI: 10.1056/NEJMcp1607526.
12. Slavin J, Distasio M, **Dellaripa PF**, Groff M. Odontoid cervical gout causing atlantoaxial instability: Case report," *J Neurosurg*. 2019.
13. Juge PA, **Dellaripa PF**, Sparks JA. Pulmonary damage biomarkers for risk of rheumatoid arthritis-associated interstitial lung disease: Enabling early detection and risk stratification. *Arthritis Rheum*. In press, 2024.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Velez NF, Ishizawar RC, **Dellaripa PF**, Laga-Canales A, Saavedra AP, Murphy GF, Fisher DC, Kupper TS, Vleugels RA. Recalcitrant Full Facial Edema: A Novel Presentation of Subcutaneous Panniculitis-like T-cell Lymphoma. First World Congress of Cutaneous Lymphomas; Chicago, IL, September 22-25, 2010.
2. Saketkoo L, Huscher D, Khanna D, **Dellaripa PF**, Flaherty K, Matteson E. ILD in the connective tissue diseases OMERACT poster presentation American College of Rheumatology, Boston, MA, 2010.
3. Skog A, **Dellaripa PF**, Peyre S. Utilization and Reliability of Medical Simulation Scenarios to Assess Leadership Styles during Transitions of Patient Acuity 11th Annual International Meeting on Simulation in Healthcare (IMSH), New Orleans, LA, 2011.
4. Saketkoo L, Huscher D, Khanna D, **Dellaripa PF**, et al. Flaherty K. Developing a Disease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise American College of Rheumatology Chicago, IL, 2011, Oral presentation.
5. Bongartz T, Matteson E, **Dellaripa PF**, Ryu JH, Crowson C, Hartman T. Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia. American College of Rheumatology, Chicago, IL, 2011.
6. Henderson L, Loring S, Gill R, Liao K, Stoll M, Kim S, **Dellaripa PF**, et al. Shrinking Lung Syndrome is a Multifactorial Process Featuring Reduced Lung Compliance and Extrinsic Ventilatory Restriction. American College of Rheumatology, Chicago, IL, 2011.
7. Saketkoo L, Huscher D, Khanna D, **Dellaripa PF**, et al. Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results from a Delphi Exercise: "Delivering a Consensus on Domains" oral

- presentation. American College of Rheumatology, Washington, DC, 2012.
8. Rao D, Wei K, Merola JF, O'Brien WR, Takvorian SU, **Dellaripa PF**, Schur PS. The significance of anti-myeloperoxidase and anti-proteinase 3 antibodies in the absence of anti-neutrophil cytoplasmic antibody immunofluorescence positivity. American College of Rheumatology, San Diego 2013.
 9. Doyle TJ, Osario JC, Madan R, Cabrel F, Rosas IO, **Dellaripa PF**. Assessment of the effect of Rituximab in the treatment of ILD associated with the antisynthetase syndrome. American College of Rheumatology 2014 Boston poster presentation.
 10. Oliviera RK, Systrom DM, Tracy JA, Karin AL, Waxman AB, **Dellaripa PF**, Hoover P. Exercise tolerance evaluation by invasive cardio pulmonary testing in connective tissue disease; Beyond pulmonary hypertension. Poster presentation. American College of Rheumatology, San Francisco 2015.
 11. Macfarlane L, **Dellaripa PF**. Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience. ACR, San Diego 2017.
 12. Doyle T, Borker P, Fletcher E, Murphy D, Rachna Madan R, **Dellaripa PF**. Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease. Abstract Poster Presentation American College of Rheumatology, Chicago 2018.
 13. **Dellaripa PF**, Doyle TJ, Danoff SK et al. Performance of RA disease activity and patient reported outcomes in RA associated ILD in a prospective trial using pirfenidone in RA ILD (TRAIL 1) ACR Annual meeting, Poster presentation 2021
 14. **Dellaripa PF**, Hoover P, Doyle TC. ACR Convergence 2022. Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy.

Narrative Report

My career, first at the Lahey Clinic and at Brigham and Women's Hospital (BWH) since 2006, has represented a blend of my interests in clinical care and clinical investigation focusing on the intersection of rheumatic diseases and pulmonary disease. I have also developed an interest in developing unique teaching programs for residents and medical students utilizing medical simulation and more recently my interest in environmental effects on lung and autoimmunity has led to my interest in climate, health and education.

At BWH, I have developed the multidisciplinary interstitial lung disease (ILD) clinic in concert with the pulmonary department, which encompasses expertise in basic science in lung fibrosis, translational research, and clinical care. Our research has shown that such a multidisciplinary approach to patients with inflammatory and fibrotic lung disease can significantly change or redirect a patient's diagnosis and care as noted in our paper in *Rheumatology*. This multidisciplinary model has been emulated at other centers. However, given the relative rarity of these diseases and the need for multi-institutional collaboration, I initiated and developed a national and international study group thru the American College of Rheumatology (ACR). This effort has led to a separate international effort to develop outcomes measures for clinical trials, known as OMERACT, with pulmonary and rheumatologic experts from around the world and has spun off newer collaborations between the ACR and the British Rheumatologic Society. I have been involved in clinical investigation in different ILD associated studies with rheumatoid arthritis (first prospective trial using antifibrotic therapy in RA ILD TRAIL1) and in the scleroderma lung study III using pirfenidone and a ongoing pilot trial using abatacept in antisynthetase syndrome related ILD. I am also a collaborator on a variety of retrospective and

prospective efforts to better understand the underlying phenotypes, natural history and molecular mechanisms associated with ILD in the connective tissue diseases. I have been invited to participate annually at the ACR national meeting to help educate physicians on the intersection of lung disease and rheumatologic disease, to write and publish in this area of clinical expertise, and to mentor young physicians who now share this interest as well. Finally, I am part of a nascent process thru the ACR to develop guidelines on the screening and treatment of lung disease and rheumatic diseases, a sorely needed tool for clinicians as we gain knowledge and treatment options for these diseases

In my role as a medical educator at BWH, I have served as the Assistant Medical Director of the Simulation Center (STRATUS). I created a simulation teaching program and curriculum that have been embedded within the inpatient teaching curriculum for the internal medical residency program. My own area of interest has been in studying the role of leadership, disclosure and leadership behavior in successful team function and I continue to communicate these concepts through a self-produced video program that is now available online during our intern orientation program in June and is used by other medical schools as a teaching tool as well. In addition, I serve in multiple CME programs thru BWH and HMS as a speaker and leadership role and continue to attend yearly on the ITU medical teaching service as attending physician.

From a community and volunteer perspective, I have been appointed to serve on the Financial Aid Advisory committee at Harvard Medical School commencing September 2018. I work in a voluntary capacity with the FDA on the rheumatology advisory committee. In addition, I continue to work with the Indian Health Service as a telemedicine educator and consultant. Also, I am a part of the newly formed Climate Action Council at BWH and HMS curriculum working group which is creating a template for physician engagement and education in the area sustainability of the health care system. I have been central in the development of a model curriculum and sustainability projects in climate and health with several housestaff who I have mentored, which led to a grassroots effort starting here at BWH and through Harvard Medical School. Finally, I initiated a nascent health and climate awareness through the ACR with two clinical sessions starting in 2021; I have authored a white paper on this topic to the ACR that was approved for submission to Arthritis and Rheumatology in December 2023.

In summary, I have been fortunate to combine my interests and training in both lung diseases and rheumatology to establish a novel clinical delivery system to enhance patient care, clinical investigation, and collaborations through the network of centers that I have established. My interests in climate science and human health emerged from interest in lung disease and has led to a new and important collaborative effort within BWH, Harvard Medical School and through the ACR. At the same time, I have sought to combine my love of teaching and communication about my areas of interest locally at BWH, at Harvard Medical School, nationally through the ACR and internationally as well.